Fulcrum Therapeutics (FULC) EBIT (2020 - 2025)
Historic EBIT for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to -$21.9 million.
- Fulcrum Therapeutics' EBIT rose 1300.64% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.2 million, marking a year-over-year decrease of 18308.6%. This contributed to the annual value of -$21.9 million for FY2024, which is 8021.31% up from last year.
- According to the latest figures from Q3 2025, Fulcrum Therapeutics' EBIT is -$21.9 million, which was up 1300.64% from -$19.8 million recorded in Q2 2025.
- Over the past 5 years, Fulcrum Therapeutics' EBIT peaked at $52.5 million during Q2 2024, and registered a low of -$34.2 million during Q2 2022.
- For the 5-year period, Fulcrum Therapeutics' EBIT averaged around -$20.4 million, with its median value being -$24.7 million (2022).
- Per our database at Business Quant, Fulcrum Therapeutics' EBIT surged by 29233.48% in 2024 and then tumbled by 13774.86% in 2025.
- Over the past 5 years, Fulcrum Therapeutics' EBIT (Quarter) stood at -$23.6 million in 2021, then fell by 18.74% to -$28.0 million in 2022, then decreased by 0.07% to -$28.0 million in 2023, then surged by 30.59% to -$19.4 million in 2024, then dropped by 12.5% to -$21.9 million in 2025.
- Its EBIT stands at -$21.9 million for Q3 2025, versus -$19.8 million for Q2 2025 and -$19.4 million for Q4 2024.